|Bid||0.00 x 0|
|Ask||300.05 x 0|
|Day's range||295.50 - 300.05|
|52-week range||265.75 - 357.85|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||19.87|
|Forward dividend & yield||9.00 (3.03%)|
|Ex-dividend date||19 Mar 2020|
|1y target est||N/A|
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Newest wave of coronavirus could be controlled with better leadership, U.S. experts say.
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.